Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
44
GWLL Quote, Financials, Valuation and Earnings
Last price:
$2.80
Seasonality move
:
-25.52%
Day range:
$2.80 - $2.80
52-week range:
$0.20 - $10.00
Dividend yield:
0%
P/E ratio:
623.05x
P/S ratio:
4,348.96x
P/B ratio:
5,175.12x
Volume:
--
Avg. volume:
72
1-year change:
1300%
Market cap:
$277.2M
Revenue:
$100
EPS (TTM):
-$0.00
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Goldenwell Biotech, Inc. has -- downside to fair value with a price target of -- per share.
GWLL vs. S&P 500
-
Over the past 5 trading days, Goldenwell Biotech, Inc. has underperformed the S&P 500 by -4.32% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Goldenwell Biotech, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Goldenwell Biotech, Inc. has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Goldenwell Biotech, Inc. reported revenues of $25K.
Earnings Growth
-
Goldenwell Biotech, Inc. has grown year-over-year earnings for 2 quarters straight. In the most recent quarter Goldenwell Biotech, Inc. reported earnings per share of -$0.00.
Enterprise value:
277.4M
EV / Invested capital:
--
Price / LTM sales:
4,348.96x
EV / EBIT:
--
EV / Revenue:
4,438.88x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-10,313.39x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-33.88%
Net Income Margin (TTM):
-113.12%
Return On Equity:
-176.34%
Return On Invested Capital:
-37.78%
Operating Margin:
-23.6%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $2.1K | $400 | $62.5K | -- | $25K | |
| Gross Profit | $1K | $100 | -- | -- | -- | |
| Operating Income | -$1M | -$122.7K | -$64.3K | -$23.1K | -$5.9K | |
| EBITDA | -$1M | -$122.7K | -$64.3K | -$23.1K | -$5.9K | |
| Diluted EPS | -$0.01 | -$0.00 | -$0.00 | -$0.00 | -$0.00 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $433.4K | $235K | $186.9K | $179.4K | $220.4K | |
| Total Assets | $485.8K | $266.1K | $186.9K | $179.4K | $220.4K | |
| Current Liabilities | $126K | $29.1K | $1.4K | $1.2K | $39.4K | |
| Total Liabilities | $154.6K | $29.1K | $81.4K | $198.7K | $315.2K | |
| Total Equity | $331.3K | $237K | $105.5K | -$19.2K | -$94.8K | |
| Total Debt | $51.5K | -- | -- | $197.5K | $275.9K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$1M | -$121K | -$26.8K | -$23.1K | -$30.9K | |
| Cash From Investing | -- | -- | -- | -- | -- | |
| Cash From Financing | $965K | $113.8K | $2.1K | $2.1K | -- | |
| Free Cash Flow | -$1M | -$121.1K | -$26.9K | -$23.1K | -$30.9K | |
GWLL
Sector
Market Cap
$277.2M
--
Price % of 52-Week High
28%
--
Dividend Yield
0%
--
Shareholder Yield
-0.13%
--
1-Year Price Total Return
1300%
--
Beta (5-Year)
--
--
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$2.88
200-day SMA
Buy
Level
$0.91
Bollinger Bands (100)
Buy
Level
-0.06 - 3.32
Chaikin Money Flow
Buy
Level
9.6K
20-day SMA
Sell
Level
$2.95
Relative Strength Index (RSI14)
Sell
Level
44.35
ADX Line
Sell
Level
15.33
Williams %R
Neutral
Level
-34.7826
50-day SMA
Sell
Level
$3.05
MACD (12, 26)
Buy
Level
0.01
25-day Aroon Oscillator
Sell
Level
-56
On Balance Volume
Neutral
Level
16K
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (34.6615)
Sell
CA Score
(Annual)
Level (-4.8387)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (9.1588)
Buy
Piotroski F Score
(Annual)
Level (4)
Buy
Quality Ratio Score
Level (3)
Buy
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Goldenwell Biotech, Inc. is a development stage company, which engages in the research & development and industrialization of healthcare products, bio-pharmaceuticals and bio-engineering drugs, and food and cosmetics products. The firm plans to develop, manufacture and market five products: Bovine Cardiac Vascular Active Peptide, Double Proline AG-3D Active Collagen Peptide, Cartilage Peptide-Type II Collagen Peptide, DNA Repair, and Sugar Master. The company was founded on August 20, 2019 and is headquartered in Solon, OH.
Stock Forecast FAQ
In the current month, GWLL has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The GWLL average analyst price target in the past 3 months is --.
-
Where Will Goldenwell Biotech, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Goldenwell Biotech, Inc. share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Goldenwell Biotech, Inc.?
Analysts are divided on their view about Goldenwell Biotech, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Goldenwell Biotech, Inc. is a Sell and believe this share price will rise from its current level to --.
-
What Is Goldenwell Biotech, Inc.'s Price Target?
The price target for Goldenwell Biotech, Inc. over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is GWLL A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Goldenwell Biotech, Inc. is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of GWLL?
You can purchase shares of Goldenwell Biotech, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Goldenwell Biotech, Inc. shares.
-
What Is The Goldenwell Biotech, Inc. Share Price Today?
Goldenwell Biotech, Inc. was last trading at $2.80 per share. This represents the most recent stock quote for Goldenwell Biotech, Inc.. Yesterday, Goldenwell Biotech, Inc. closed at $2.80 per share.
-
How To Buy Goldenwell Biotech, Inc. Stock Online?
In order to purchase Goldenwell Biotech, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get GWLL Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
GWLL
Sector
P/E ratio
623.05x
--
PEG ratio
--
--
P/B ratio
5,175.12x
--
Price / LTM sales
4,348.96x
--
Growth Metrics
GWLL
Sector
Revenue growth
17885.61%
--
Earnings growth
80%
--
Revenue (5-year growth)
--
--
Earnings forecast
--
--
Profitability
GWLL
Sector
Profitability FY 2024
$100
--
Return on invested capital
-37.78%
--
Return on assets
-33.88%
--
Return on equity
-176.34%
--
Earnings Date
Last Earnings Date
Jan
8
Next Earnings Date
Jan
8
Estimated Next Earnings Date
Apr
9
Balance Sheet
GWLL
Sector
Total cash
$45.6K
--
Short term investments
--
--
Total assets
$224.2K
--
Long term debt
$275.9K
--
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Sell
48
Is GOOGL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
69
RGC alert for Jan 8
Regencell Bioscience Holdings Ltd. [RGC] is up 58.95% over the past day.
Buy
69
WDC alert for Jan 8
Western Digital Corp. [WDC] is down 8.88% over the past day.
Sell
38
CRNX alert for Jan 8
Crinetics Pharmaceuticals, Inc. [CRNX] is up 16.08% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
